Finance / United States
Roche Offers US$43.7bn for Genentech
July 2008 | In The NewsIn a deal that could blow the rest of 2008's pharmaceutical acquisitions out of the water, Swiss drugmaker Roche has offered to buy the remaining shares US biotechnology giant Genentech for US$43.7bn. Roche - which currently owns a majority 55.9% share in the US firm - offered US$89 per share, an 8.8% premium on closing price.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
Free Trial to CFW
Register here for your FREE 7-day trial to Corporate Financing Week!
TAKE A TRIAL >>
